Afuco™ Anti-Human CXCL8 ADCC Therapeutic Antibody (ABX-IL8), ADCC Enhanced
Anti-CXCL8 ADCC Enhanced Antibody (ABX-IL8) is an ADCC enhanced antibody produced by our Afuco™ platform. This is a human IgG2 monoclonal antibody directed against human IL-8, which should be considered as a treatment modality for other solid tumors in which IL-8 plays an angiogenic role, including bladder, prostate, ovarian and lung cancers. ABX-IL8 was shown to be safe and well tolerated in both the single-dose and the multiple dose trials. No serious or unexpected adverse events have been reported, no immunogenicity has been detected, and there has been no evidence of cytokine release syndrome in either of the trials.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-191CL |
| Pricing | Inquiry |
| Host | Human |
| Target | CXCL8 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | Store the antibody (in aliquots) at -20°C. Avoid repeated freezing and thawing of samples. |